Group 1 - The article discusses the potential of Verastem, Inc. (VSTM) and highlights the RAMP-203 study as a significant opportunity for the company, particularly regarding the Avutometinib combination therapy [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis and a model portfolio of biotech stocks [2] - The Biotech Analysis Central service includes over 600 articles and aims to assist healthcare investors in making informed decisions [2] Group 2 - The article does not contain any specific financial data or performance metrics related to Verastem, Inc. or the biotech industry [1][3][4]